NewsBenzingaOppenheimer Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $50 Oppenheimer Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $50 Benzinga 2026.09.23 12:08 (GMT+0) Open on Benzinga Other news BTIG Reiterates Buy on Nexxen International, Maintains $13 Price Target Morgan Stanley Maintains Equal-Weight on Xcel Energy, Raises Price Target to $85 Morgan Stanley Maintains Equal-Weight on Western Midstream, Lowers Price Target to $52 Morgan Stanley Maintains Overweight on Vistra, Lowers Price Target to $226 Alaska Air Gr Q3 2026 Earnings Call Transcript If You Invested $1000 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today
